Complete diagnostic work-up provides the rational basis for the most appropriate therapy of myelodysplastic syndromes

Abstract

Myelodysplastic syndromes are now classified according to the 2008 World Health Organization criteria. An accurate risk assessment requires a keen evaluation of disease-related factors to adapt treatment to patients age, expectations and comorbidities. A high proportion of MDS patients are not eligible for potentially curative and consequently intensive treatment because of advanced age and/or clinically relevant comorbidities and poor performance status. In these patients, a number of new agents are available or being developed but their use should be carefully guided by the chromosomal and genetic determinant of the disease.